Publications by authors named "Peter Working"

Claim this Profile
P
Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease.
Andrew A Badachhape, Peter K Working, Mayank Srivastava, Prajwal Bhandari, Igor V Stupin

Sci Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Eric J Small, Michael A Carducci, James M Burke, Ron Rodriguez, Lawrence Fong, Peter Working

Mol Ther· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
Yuanhao Li, Neeraja Idamakanti, Trini Arroyo, Steve Thorne, Tony Reid, Peter Working

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses.
Peter K Working, Andy Lin, Flavia Borellini

Oncogene· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Jeanette Dilley, Seshidhar Reddy, Derek Ko, Natalie Nguyen, Ginny Rojas, Peter Working

Cancer Gene Ther· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NTP-CERHR expert panel report on the reproductive and developmental toxicity of acrylamide.
Jeanne Manson, Michael J Brabec, Judy Buelke-Sam, Gary P Carlson, Robert E Chapin, Peter Working

Birth Defects Res B Dev Reprod Toxicol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
David M Vail, Michael A Amantea, Gail T Colbern, Francis J Martin, Ralf A Hilger, Peter K Working

Semin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
William C Zamboni, Anne C Gervais, Merrill J Egorin, Jan H M Schellens, Elleanor G Zuhowski, Peter K Working

Cancer Chemother Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy.
Yuanhao Li, Yu Chen, Jeanette Dilley, Trini Arroyo, Derek Ko, Peter Working

Mol Cancer Ther· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectively replicating oncolytic adenoviruses as cancer therapeutics.
De-Chao Yu, Peter Working, Dale Ando

Curr Opin Mol Ther· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Irma A J M Bakker-Woudenberg, Marian T ten Kate, Luke Guo, Peter Working, Johan W Mouton

Antimicrob Agents Chemother· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
David M Vail, Ilene D Kurzman, Phyllis C Glawe, Maura G O'Brien, Ruthanne Chun, Peter K Working

Cancer Chemother Pharmacol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Jane Zhang, Nagarajan Ramesh, Yu Chen, Yuanhao Li, Jeanette Dilley, Peter Working

Cancer Res· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis